XtalPi Holdings Limited: Business Overview, Financials & Competitive Analysis
XtalPi Holdings Limited scores 6/10 on the AskCyborg Cyborg Score (Solid). Promising AI-pharma platform with blockbuster partnerships but pre-profitability economics requiring substantial top-line acceleration to justify valuation. XtalPi demonstrates strong AI-powered technology differentiation and established pharma partnerships, evidenced by a substantial market cap and recent strategic wins. However, financial metrics reveal concerning profitability (ROE of 2.01%, ROIC of -16.28%) and.
What is XtalPi Holdings Limited's industry? XtalPi Holdings Limited (xtalpi.com) operates in Drug Discovery Services. AskCyborg classifies XtalPi Holdings Limited under Drug Discovery Services in its company registry.
XtalPi Holdings Ltd is a research platform company powered by artificial intelligence (AI) and robotics, dedicated to driving intelligent and digital transformation in the life sciences and materials sciences sectors....
Cyborg Score thesis
Promising AI-pharma platform with blockbuster partnerships but pre-profitability economics requiring substantial top-line...
Read the full analyst-debate transcript →Get the Latest XtalPi Holdings Limited Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeXtalPi Holdings Limited Overview
Pro stress-test →XtalPi Holdings Ltd is a research platform company powered by artificial intelligence (AI) and robotics, dedicated to driving intelligent and digital transformation in the life sciences and materials sciences sectors. The company combines quantum physics, AI, cloud computing, and large-scale robotics to provide research & development solutions, services, and products for pharmaceuticals, biotechnology, renewable energy, and materials industries globally.
Strategic Profile
Pro stress-test →The company generates the majority of its revenue from drug discovery solutions, and a smaller portion of revenue is derived from AI for Science intelligent solutions. The company has a strategic collaboration with Pfizer to co-build an AI-driven molecular simulation research and development platform and partnerships with other biopharmaceutical companies for therapeutic development.
Competitive Landscape
Pro stress-test →XtalPi competes with hybrid AI-pharma platforms including Schrodinger (drug discovery informatics), Atomwise (AI molecular screening), and traditional contract research organizations (CROs) like Syneos Health and Charles River Labs. Unlike pure software vendors, XtalPi differentiates through integrated robotics automation and clinical-stage drug development, though competitors like Schrodinger have achieved greater scale and profitability. Partnership with Pfizer elevates competitive positioning but also reveals reliance on pharma partnerships for validation.
Industry Context
XtalPi Holdings Limited operates in Drug Discovery Services.
Key facts
Founded: 2015 · Headquarters: Shenzhen, China · Employees: Not disclosed · Revenue: HKD 893.17 million (trailing 12 months) · Market cap: HKD 41.31 billion (~$5.3 billion USD equivalent)